Stephanie Anne Kronenberg
Memorial Sloan Kettering Cancer Center · 7 works · 4,518 citations · h-index 7
Top works
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
- Survival, Response Duration, and Activity By Braf Mutation (Mt) Status in a Phase 1 Trial of Nivolumab (Anti-Pd-1, Bms-936558, Ono-4538) and Ipilimumab (Ipi) Concurrent Therapy in Advanced Melanoma (Mel)
- A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer.
- Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL).
- Melanoma and immunotherapy bridge 2015
- Concurrent Radiation Therapy (RT), Ipilimumab (Ipi) and/or Nivolumab (Nivo) on a Phase 1 Clinical Trial